A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
Influenza, Human
About this trial
This is an interventional prevention trial for Influenza, Human focused on measuring Grippe, Flu, Influenza, Vaccine, RNA vaccine, Self-amplifying
Eligibility Criteria
Inclusion Criteria:
- Male or female participants 18 to 49 years of age.
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Male participant who is able to father children and willing to use an acceptable method of contraception; or female participant not of childbearing potential; or male participant not able to father children.
- Capable of giving signed informed consent.
Exclusion Criteria:
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- Women who are pregnant or breastfeeding.
- Allergy to egg proteins (egg or egg products) or chicken proteins.
- Participant who has had significant exposure to laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection), coronavirus disease 2019 (COVID-19), or influenza in the past 14 days known prior to Visit 1
- Any participant who has a SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior to Visit 1 that has not been confirmed as negative.
- Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
- Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study.
- Vaccination with any influenza vaccine within 6 months (175 days) before study intervention administration.
- Any participant who has received or plans to receive a nucleoside-modified messenger ribonucleic acid (modRNA)-platform SARS-CoV-2 vaccine within 60 days of Visit 1
- Previous vaccination with an saRNA or an alphavirus replicon vaccine preparation.
- Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
- Screening hematology/blood chemistry lab >=Grade 1 abnormality. Except Bilirubin, other stable Grade1 abnormalities may be considered eligible by Investigator.
- Screening electrocardiogram (ECG) that is consistent with probable or possible myocarditis or pericarditis, or demonstrates clinically relevant abnormalities that may affect participant safety or study results.
- Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
- Participation in strenuous or endurance exercise through Visit 3.
- Prior history of heart disease.
Sites / Locations
- Arizona Heart Rhythm Center
- Hope Research Institute
- The Pain Center of Arizona
- Diablo Clinical Research, Inc.
- Finlay Medical Research
- Mount Sinai Hospital
- Panax Clinical Research
- Advanced Pharma CR, LLC
- Miami Clinical Research
- Pines Care Research Center, LLC
- Pinnacle Health Care Center
- Comprehensive Cardiology Consultants
- Great Lakes Clinical Trials - Andersonville
- Pioneer Heart Institute
- Meridian Clinical Research, LLC
- Velocity Clinical Research, Omaha
- NYU Langone Health
- SUNY Upstate Medical University Global Health Laboratory
- SUNY Upstate Medical University Institute for Global Health
- SUNY Upstate Medical University
- CTI Clinical Research Center
- Coastal Carolina Research Center
- Benchmark Research
- Eric S. Tiblier, MD
- DM Clinical Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Arm 15
Arm 16
Arm 17
Arm 18
Arm 19
Arm 20
Arm 21
Arm 22
Arm 23
Arm 24
Arm 25
Arm 26
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Active Comparator
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
PF-07852352 Influenza saRNA, low dose
PF-07852352 Influenza saRNA, mid dose
PF-07852352 Influenza saRNA, high dose
PF-07836391 Influenza saRNA, low dose
PF-07836391 Influenza saRNA, mid dose
PF-07836391 Influenza saRNA, high dose
PF-07836394 Influenza saRNA, low dose
PF-07836394 Influenza saRNA, mid dose
PF-07836394 Influenza saRNA, high dose
PF-07836395 Influenza saRNA, low dose
PF-07836395 Influenza saRNA, mid dose
PF-07836395 Influenza saRNA, high dose
PF-07836396 Influenza saRNA, low dose
PF-07836396 Influenza saRNA, mid dose
PF-07836396 Influenza saRNA, high dose
PF-07867246 Influenza saRNA, mid dose
PF-07867246 Influenza saRNA, low dose
PF-07867246 Influenza saRNA, high dose
Placebo
Quadrivalent influenza vaccine (QIV)
PF-07871987 Influenza saRNA, low dose
PF-07871987 Influenza saRNA, mid dose
PF-07871987 Influenza saRNA, high dose
PF-07914705 Influenza saRNA mid dose
PF-07914705 Influenza saRNA, high dose
PF-07915048 Influenza saRNA, high dose